- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Spinal Muscular Atrophy Medicine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Spinal Muscular Atrophy Medicine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Spinal Muscular Atrophy Medicine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While LMI-070 segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Spinal Muscular Atrophy Medicine include Astellas Pharma Inc., AveXis, Inc., Bioblast Pharma Ltd., Cytokinetics, Inc. 24, and F. Hoffmann-La Roche Ltd., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Spinal Muscular Atrophy Medicine market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
LMI-070
ND-602
NT-1654
Nusinersen
NXD-30001
Others
Market segment by Application can be divided into
Hospital
Clinic
Others
The key market players for global Spinal Muscular Atrophy Medicine market are listed below:
Astellas Pharma Inc.
AveXis, Inc.
Bioblast Pharma Ltd.
Cytokinetics, Inc. 24
F. Hoffmann-La Roche Ltd.
Genethon
Genzyme Corporation
GMP-Orphan SAS
Ionis Pharmaceuticals, Inc.
Longevity Biotech, Inc
Neurodyn Inc.
Neurotune AG
Novartis AG
Sarepta Therapeutics, Inc.
Voyager Therapeutics, Inc.
Vybion, Inc.
WAVE Life Sciences Ltd.
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Spinal Muscular Atrophy Medicine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Spinal Muscular Atrophy Medicine, with price, sales, revenue and global market share of Spinal Muscular Atrophy Medicine from 2019 to 2022.
Chapter 3, the Spinal Muscular Atrophy Medicine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Spinal Muscular Atrophy Medicine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Spinal Muscular Atrophy Medicine market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Spinal Muscular Atrophy Medicine.
Chapter 13, 14, and 15, to describe Spinal Muscular Atrophy Medicine sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Spinal Muscular Atrophy Medicine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Spinal Muscular Atrophy Medicine Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 LMI-070
1.2.3 ND-602
1.2.4 NT-1654
1.2.5 Nusinersen
1.2.6 NXD-30001
1.2.7 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Spinal Muscular Atrophy Medicine Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Spinal Muscular Atrophy Medicine Market Size & Forecast
1.4.1 Global Spinal Muscular Atrophy Medicine Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Spinal Muscular Atrophy Medicine Sales in Volume (2017-2028)
1.4.3 Global Spinal Muscular Atrophy Medicine Price (2017-2028)
1.5 Global Spinal Muscular Atrophy Medicine Production Capacity Analysis
1.5.1 Global Spinal Muscular Atrophy Medicine Total Production Capacity (2017-2028)
1.5.2 Global Spinal Muscular Atrophy Medicine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Spinal Muscular Atrophy Medicine Market Drivers
1.6.2 Spinal Muscular Atrophy Medicine Market Restraints
1.6.3 Spinal Muscular Atrophy Medicine Trends Analysis
2 Manufacturers Profiles
2.1 Astellas Pharma Inc.
2.1.1 Astellas Pharma Inc. Details
2.1.2 Astellas Pharma Inc. Major Business
2.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product and Services
2.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 AveXis, Inc.
2.2.1 AveXis, Inc. Details
2.2.2 AveXis, Inc. Major Business
2.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.2.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Bioblast Pharma Ltd.
2.3.1 Bioblast Pharma Ltd. Details
2.3.2 Bioblast Pharma Ltd. Major Business
2.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product and Services
2.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Cytokinetics, Inc. 24
2.4.1 Cytokinetics, Inc. 24 Details
2.4.2 Cytokinetics, Inc. 24 Major Business
2.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product and Services
2.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 F. Hoffmann-La Roche Ltd.
2.5.1 F. Hoffmann-La Roche Ltd. Details
2.5.2 F. Hoffmann-La Roche Ltd. Major Business
2.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product and Services
2.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Genethon
2.6.1 Genethon Details
2.6.2 Genethon Major Business
2.6.3 Genethon Spinal Muscular Atrophy Medicine Product and Services
2.6.4 Genethon Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Genzyme Corporation
2.7.1 Genzyme Corporation Details
2.7.2 Genzyme Corporation Major Business
2.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Product and Services
2.7.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 GMP-Orphan SAS
2.8.1 GMP-Orphan SAS Details
2.8.2 GMP-Orphan SAS Major Business
2.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product and Services
2.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Ionis Pharmaceuticals, Inc.
2.9.1 Ionis Pharmaceuticals, Inc. Details
2.9.2 Ionis Pharmaceuticals, Inc. Major Business
2.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Longevity Biotech, Inc
2.10.1 Longevity Biotech, Inc Details
2.10.2 Longevity Biotech, Inc Major Business
2.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product and Services
2.10.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Neurodyn Inc.
2.11.1 Neurodyn Inc. Details
2.11.2 Neurodyn Inc. Major Business
2.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product and Services
2.11.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Neurotune AG
2.12.1 Neurotune AG Details
2.12.2 Neurotune AG Major Business
2.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Product and Services
2.12.4 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Novartis AG
2.13.1 Novartis AG Details
2.13.2 Novartis AG Major Business
2.13.3 Novartis AG Spinal Muscular Atrophy Medicine Product and Services
2.13.4 Novartis AG Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Sarepta Therapeutics, Inc.
2.14.1 Sarepta Therapeutics, Inc. Details
2.14.2 Sarepta Therapeutics, Inc. Major Business
2.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.14.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Voyager Therapeutics, Inc.
2.15.1 Voyager Therapeutics, Inc. Details
2.15.2 Voyager Therapeutics, Inc. Major Business
2.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.15.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 Vybion, Inc.
2.16.1 Vybion, Inc. Details
2.16.2 Vybion, Inc. Major Business
2.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Product and Services
2.16.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17 WAVE Life Sciences Ltd.
2.17.1 WAVE Life Sciences Ltd. Details
2.17.2 WAVE Life Sciences Ltd. Major Business
2.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product and Services
2.17.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Spinal Muscular Atrophy Medicine Breakdown Data by Manufacturer
3.1 Global Spinal Muscular Atrophy Medicine Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Spinal Muscular Atrophy Medicine Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Spinal Muscular Atrophy Medicine
3.4 Market Concentration Rate
3.4.1 Top 3 Spinal Muscular Atrophy Medicine Manufacturer Market Share in 2021
3.4.2 Top 6 Spinal Muscular Atrophy Medicine Manufacturer Market Share in 2021
3.5 Global Spinal Muscular Atrophy Medicine Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Spinal Muscular Atrophy Medicine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Spinal Muscular Atrophy Medicine Market Size by Region
4.1.1 Global Spinal Muscular Atrophy Medicine Sales in Volume by Region (2017-2028)
4.1.2 Global Spinal Muscular Atrophy Medicine Revenue by Region (2017-2028)
4.2 North America Spinal Muscular Atrophy Medicine Revenue (2017-2028)
4.3 Europe Spinal Muscular Atrophy Medicine Revenue (2017-2028)
4.4 Asia-Pacific Spinal Muscular Atrophy Medicine Revenue (2017-2028)
4.5 South America Spinal Muscular Atrophy Medicine Revenue (2017-2028)
4.6 Middle East and Africa Spinal Muscular Atrophy Medicine Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Spinal Muscular Atrophy Medicine Sales in Volume by Type (2017-2028)
5.2 Global Spinal Muscular Atrophy Medicine Revenue by Type (2017-2028)
5.3 Global Spinal Muscular Atrophy Medicine Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Spinal Muscular Atrophy Medicine Sales in Volume by Application (2017-2028)
6.2 Global Spinal Muscular Atrophy Medicine Revenue by Application (2017-2028)
6.3 Global Spinal Muscular Atrophy Medicine Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Spinal Muscular Atrophy Medicine Sales by Type (2017-2028)
7.2 North America Spinal Muscular Atrophy Medicine Sales by Application (2017-2028)
7.3 North America Spinal Muscular Atrophy Medicine Market Size by Country
7.3.1 North America Spinal Muscular Atrophy Medicine Sales in Volume by Country (2017-2028)
7.3.2 North America Spinal Muscular Atrophy Medicine Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Spinal Muscular Atrophy Medicine Sales by Type (2017-2028)
8.2 Europe Spinal Muscular Atrophy Medicine Sales by Application (2017-2028)
8.3 Europe Spinal Muscular Atrophy Medicine Market Size by Country
8.3.1 Europe Spinal Muscular Atrophy Medicine Sales in Volume by Country (2017-2028)
8.3.2 Europe Spinal Muscular Atrophy Medicine Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Type (2017-2028)
9.2 Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Application (2017-2028)
9.3 Asia-Pacific Spinal Muscular Atrophy Medicine Market Size by Region
9.3.1 Asia-Pacific Spinal Muscular Atrophy Medicine Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Spinal Muscular Atrophy Medicine Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Spinal Muscular Atrophy Medicine Sales by Type (2017-2028)
10.2 South America Spinal Muscular Atrophy Medicine Sales by Application (2017-2028)
10.3 South America Spinal Muscular Atrophy Medicine Market Size by Country
10.3.1 South America Spinal Muscular Atrophy Medicine Sales in Volume by Country (2017-2028)
10.3.2 South America Spinal Muscular Atrophy Medicine Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Type (2017-2028)
11.2 Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Application (2017-2028)
11.3 Middle East & Africa Spinal Muscular Atrophy Medicine Market Size by Country
11.3.1 Middle East & Africa Spinal Muscular Atrophy Medicine Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Spinal Muscular Atrophy Medicine Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Spinal Muscular Atrophy Medicine and Key Manufacturers
12.2 Manufacturing Costs Percentage of Spinal Muscular Atrophy Medicine
12.3 Spinal Muscular Atrophy Medicine Production Process
12.4 Spinal Muscular Atrophy Medicine Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Spinal Muscular Atrophy Medicine Typical Distributors
13.3 Spinal Muscular Atrophy Medicine Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global Spinal Muscular Atrophy Medicine Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Spinal Muscular Atrophy Medicine Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Astellas Pharma Inc. Basic Information, Manufacturing Base and Competitors
Table 4. Astellas Pharma Inc. Major Business
Table 5. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 6. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. AveXis, Inc. Basic Information, Manufacturing Base and Competitors
Table 8. AveXis, Inc. Major Business
Table 9. AveXis, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 10. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Bioblast Pharma Ltd. Basic Information, Manufacturing Base and Competitors
Table 12. Bioblast Pharma Ltd. Major Business
Table 13. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product and Services
Table 14. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Cytokinetics, Inc. 24 Basic Information, Manufacturing Base and Competitors
Table 16. Cytokinetics, Inc. 24 Major Business
Table 17. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product and Services
Table 18. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. F. Hoffmann-La Roche Ltd. Basic Information, Manufacturing Base and Competitors
Table 20. F. Hoffmann-La Roche Ltd. Major Business
Table 21. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product and Services
Table 22. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Genethon Basic Information, Manufacturing Base and Competitors
Table 24. Genethon Major Business
Table 25. Genethon Spinal Muscular Atrophy Medicine Product and Services
Table 26. Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Genzyme Corporation Basic Information, Manufacturing Base and Competitors
Table 28. Genzyme Corporation Major Business
Table 29. Genzyme Corporation Spinal Muscular Atrophy Medicine Product and Services
Table 30. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. GMP-Orphan SAS Basic Information, Manufacturing Base and Competitors
Table 32. GMP-Orphan SAS Major Business
Table 33. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product and Services
Table 34. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Ionis Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 36. Ionis Pharmaceuticals, Inc. Major Business
Table 37. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 38. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Longevity Biotech, Inc Basic Information, Manufacturing Base and Competitors
Table 40. Longevity Biotech, Inc Major Business
Table 41. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product and Services
Table 42. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Neurodyn Inc. Basic Information, Manufacturing Base and Competitors
Table 44. Neurodyn Inc. Major Business
Table 45. Neurodyn Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 46. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Neurotune AG Basic Information, Manufacturing Base and Competitors
Table 48. Neurotune AG Major Business
Table 49. Neurotune AG Spinal Muscular Atrophy Medicine Product and Services
Table 50. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 52. Novartis AG Major Business
Table 53. Novartis AG Spinal Muscular Atrophy Medicine Product and Services
Table 54. Novartis AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Sarepta Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 56. Sarepta Therapeutics, Inc. Major Business
Table 57. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 58. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 59. Voyager Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 60. Voyager Therapeutics, Inc. Major Business
Table 61. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 62. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 63. Vybion, Inc. Basic Information, Manufacturing Base and Competitors
Table 64. Vybion, Inc. Major Business
Table 65. Vybion, Inc. Spinal Muscular Atrophy Medicine Product and Services
Table 66. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 67. WAVE Life Sciences Ltd. Basic Information, Manufacturing Base and Competitors
Table 68. WAVE Life Sciences Ltd. Major Business
Table 69. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product and Services
Table 70. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 71. Global Spinal Muscular Atrophy Medicine Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Pcs)
Table 72. Global Spinal Muscular Atrophy Medicine Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 73. Market Position of Manufacturers in Spinal Muscular Atrophy Medicine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 74. Global Spinal Muscular Atrophy Medicine Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 75. Head Office and Spinal Muscular Atrophy Medicine Production Site of Key Manufacturer
Table 76. Spinal Muscular Atrophy Medicine New Entrant and Capacity Expansion Plans
Table 77. Spinal Muscular Atrophy Medicine Mergers & Acquisitions in the Past Five Years
Table 78. Global Spinal Muscular Atrophy Medicine Sales by Region (2017-2022) & (K Pcs)
Table 79. Global Spinal Muscular Atrophy Medicine Sales by Region (2023-2028) & (K Pcs)
Table 80. Global Spinal Muscular Atrophy Medicine Revenue by Region (2017-2022) & (USD Million)
Table 81. Global Spinal Muscular Atrophy Medicine Revenue by Region (2023-2028) & (USD Million)
Table 82. Global Spinal Muscular Atrophy Medicine Sales by Type (2017-2022) & (K Pcs)
Table 83. Global Spinal Muscular Atrophy Medicine Sales by Type (2023-2028) & (K Pcs)
Table 84. Global Spinal Muscular Atrophy Medicine Revenue by Type (2017-2022) & (USD Million)
Table 85. Global Spinal Muscular Atrophy Medicine Revenue by Type (2023-2028) & (USD Million)
Table 86. Global Spinal Muscular Atrophy Medicine Price by Type (2017-2022) & (USD/Pcs)
Table 87. Global Spinal Muscular Atrophy Medicine Price by Type (2023-2028) & (USD/Pcs)
Table 88. Global Spinal Muscular Atrophy Medicine Sales by Application (2017-2022) & (K Pcs)
Table 89. Global Spinal Muscular Atrophy Medicine Sales by Application (2023-2028) & (K Pcs)
Table 90. Global Spinal Muscular Atrophy Medicine Revenue by Application (2017-2022) & (USD Million)
Table 91. Global Spinal Muscular Atrophy Medicine Revenue by Application (2023-2028) & (USD Million)
Table 92. Global Spinal Muscular Atrophy Medicine Price by Application (2017-2022) & (USD/Pcs)
Table 93. Global Spinal Muscular Atrophy Medicine Price by Application (2023-2028) & (USD/Pcs)
Table 94. North America Spinal Muscular Atrophy Medicine Sales by Country (2017-2022) & (K Pcs)
Table 95. North America Spinal Muscular Atrophy Medicine Sales by Country (2023-2028) & (K Pcs)
Table 96. North America Spinal Muscular Atrophy Medicine Revenue by Country (2017-2022) & (USD Million)
Table 97. North America Spinal Muscular Atrophy Medicine Revenue by Country (2023-2028) & (USD Million)
Table 98. North America Spinal Muscular Atrophy Medicine Sales by Type (2017-2022) & (K Pcs)
Table 99. North America Spinal Muscular Atrophy Medicine Sales by Type (2023-2028) & (K Pcs)
Table 100. North America Spinal Muscular Atrophy Medicine Sales by Application (2017-2022) & (K Pcs)
Table 101. North America Spinal Muscular Atrophy Medicine Sales by Application (2023-2028) & (K Pcs)
Table 102. Europe Spinal Muscular Atrophy Medicine Sales by Country (2017-2022) & (K Pcs)
Table 103. Europe Spinal Muscular Atrophy Medicine Sales by Country (2023-2028) & (K Pcs)
Table 104. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2017-2022) & (USD Million)
Table 105. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2023-2028) & (USD Million)
Table 106. Europe Spinal Muscular Atrophy Medicine Sales by Type (2017-2022) & (K Pcs)
Table 107. Europe Spinal Muscular Atrophy Medicine Sales by Type (2023-2028) & (K Pcs)
Table 108. Europe Spinal Muscular Atrophy Medicine Sales by Application (2017-2022) & (K Pcs)
Table 109. Europe Spinal Muscular Atrophy Medicine Sales by Application (2023-2028) & (K Pcs)
Table 110. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Region (2017-2022) & (K Pcs)
Table 111. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Region (2023-2028) & (K Pcs)
Table 112. Asia-Pacific Spinal Muscular Atrophy Medicine Revenue by Region (2017-2022) & (USD Million)
Table 113. Asia-Pacific Spinal Muscular Atrophy Medicine Revenue by Region (2023-2028) & (USD Million)
Table 114. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Type (2017-2022) & (K Pcs)
Table 115. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Type (2023-2028) & (K Pcs)
Table 116. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Application (2017-2022) & (K Pcs)
Table 117. Asia-Pacific Spinal Muscular Atrophy Medicine Sales by Application (2023-2028) & (K Pcs)
Table 118. South America Spinal Muscular Atrophy Medicine Sales by Country (2017-2022) & (K Pcs)
Table 119. South America Spinal Muscular Atrophy Medicine Sales by Country (2023-2028) & (K Pcs)
Table 120. South America Spinal Muscular Atrophy Medicine Revenue by Country (2017-2022) & (USD Million)
Table 121. South America Spinal Muscular Atrophy Medicine Revenue by Country (2023-2028) & (USD Million)
Table 122. South America Spinal Muscular Atrophy Medicine Sales by Type (2017-2022) & (K Pcs)
Table 123. South America Spinal Muscular Atrophy Medicine Sales by Type (2023-2028) & (K Pcs)
Table 124. South America Spinal Muscular Atrophy Medicine Sales by Application (2017-2022) & (K Pcs)
Table 125. South America Spinal Muscular Atrophy Medicine Sales by Application (2023-2028) & (K Pcs)
Table 126. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Region (2017-2022) & (K Pcs)
Table 127. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Region (2023-2028) & (K Pcs)
Table 128. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue by Region (2017-2022) & (USD Million)
Table 129. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue by Region (2023-2028) & (USD Million)
Table 130. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Type (2017-2022) & (K Pcs)
Table 131. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Type (2023-2028) & (K Pcs)
Table 132. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Application (2017-2022) & (K Pcs)
Table 133. Middle East & Africa Spinal Muscular Atrophy Medicine Sales by Application (2023-2028) & (K Pcs)
Table 134. Spinal Muscular Atrophy Medicine Raw Material
Table 135. Key Manufacturers of Spinal Muscular Atrophy Medicine Raw Materials
Table 136. Direct Channel Pros & Cons
Table 137. Indirect Channel Pros & Cons
Table 138. Spinal Muscular Atrophy Medicine Typical Distributors
Table 139. Spinal Muscular Atrophy Medicine Typical Customers
List of Figures
Figure 1. Spinal Muscular Atrophy Medicine Picture
Figure 2. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type in 2021
Figure 3. LMI-070
Figure 4. ND-602
Figure 5. NT-1654
Figure 6. Nusinersen
Figure 7. NXD-30001
Figure 8. Others
Figure 9. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application in 2021
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Global Spinal Muscular Atrophy Medicine Revenue, (USD Million) & (K Pcs): 2017 & 2021 & 2028
Figure 14. Global Spinal Muscular Atrophy Medicine Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global Spinal Muscular Atrophy Medicine Sales (2017-2028) & (K Pcs)
Figure 16. Global Spinal Muscular Atrophy Medicine Price (2017-2028) & (USD/Pcs)
Figure 17. Global Spinal Muscular Atrophy Medicine Production Capacity (2017-2028) & (K Pcs)
Figure 18. Global Spinal Muscular Atrophy Medicine Production Capacity by Geographic Region: 2022 VS 2028
Figure 19. Spinal Muscular Atrophy Medicine Market Drivers
Figure 20. Spinal Muscular Atrophy Medicine Market Restraints
Figure 21. Spinal Muscular Atrophy Medicine Market Trends
Figure 22. Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturer in 2021
Figure 23. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Manufacturer in 2021
Figure 24. Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 25. Top 3 Spinal Muscular Atrophy Medicine Manufacturer (Revenue) Market Share in 2021
Figure 26. Top 6 Spinal Muscular Atrophy Medicine Manufacturer (Revenue) Market Share in 2021
Figure 27. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2017-2028)
Figure 28. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2017-2028)
Figure 29. North America Spinal Muscular Atrophy Medicine Revenue (2017-2028) & (USD Million)
Figure 30. Europe Spinal Muscular Atrophy Medicine Revenue (2017-2028) & (USD Million)
Figure 31. Asia-Pacific Spinal Muscular Atrophy Medicine Revenue (2017-2028) & (USD Million)
Figure 32. South America Spinal Muscular Atrophy Medicine Revenue (2017-2028) & (USD Million)
Figure 33. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue (2017-2028) & (USD Million)
Figure 34. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2017-2028)
Figure 35. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2017-2028)
Figure 36. Global Spinal Muscular Atrophy Medicine Price by Type (2017-2028) & (USD/Pcs)
Figure 37. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2017-2028)
Figure 38. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2017-2028)
Figure 39. Global Spinal Muscular Atrophy Medicine Price by Application (2017-2028) & (USD/Pcs)
Figure 40. North America Spinal Muscular Atrophy Medicine Sales Market Share by Type (2017-2028)
Figure 41. North America Spinal Muscular Atrophy Medicine Sales Market Share by Application (2017-2028)
Figure 42. North America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2017-2028)
Figure 43. North America Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2017-2028)
Figure 44. United States Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Canada Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Mexico Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Type (2017-2028)
Figure 48. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Application (2017-2028)
Figure 49. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country (2017-2028)
Figure 50. Europe Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2017-2028)
Figure 51. Germany Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Region (2017-2028)
Figure 59. Asia-Pacific Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2017-2028)
Figure 60. China Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Korea Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America Spinal Muscular Atrophy Medicine Sales Market Share by Type (2017-2028)
Figure 67. South America Spinal Muscular Atrophy Medicine Sales Market Share by Application (2017-2028)
Figure 68. South America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2017-2028)
Figure 69. South America Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2017-2028)
Figure 70. Brazil Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Type (2017-2028)
Figure 73. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Application (2017-2028)
Figure 74. Middle East & Africa Spinal Muscular Atrophy Medicine Sales Market Share by Region (2017-2028)
Figure 75. Middle East & Africa Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2017-2028)
Figure 76. Turkey Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Egypt Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Saudi Arabia Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. South Africa Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Manufacturing Cost Structure Analysis of Spinal Muscular Atrophy Medicine in 2021
Figure 81. Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine
Figure 82. Spinal Muscular Atrophy Medicine Industrial Chain
Figure 83. Sales Channel: Direct Channel vs Indirect Channel
Figure 84. Methodology
Figure 85. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
